<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">818</journal-id><journal-id journal-id-type="pmc-domain">wjg</journal-id><journal-id journal-id-type="publisher-id">WJG</journal-id><journal-title-group><journal-title>World Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1007-9327</issn><issn pub-type="epub">2219-2840</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4656629</article-id><article-id pub-id-type="pmcid-ver">PMC4656629.1</article-id><article-id pub-id-type="pmcaid">4656629</article-id><article-id pub-id-type="pmcaiid">4656629</article-id><article-id pub-id-type="pmid">11833074</article-id><article-id pub-id-type="doi">10.3748/wjg.v8.i1.69</article-id><article-id pub-id-type="other">jWJG.v8.i1.pg69</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Liver Cancer</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb <sup>188</sup>Re-HAb18</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lou</surname><given-names initials="C">Chao</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="ZN">Zhi-Nan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bian</surname><given-names initials="HJ">Hui-Jie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="SB">Shou-Bo</given-names></name></contrib><aff>Chao Lou, Zhi-Nan Chen, Hui-Jie Bian, Department of Cell Engineering Research Centre, Jie Li, Department of Oral Cell Biology, Qingdu Hospital, Fourth Military Medical University, Xi&#8217;an 710033, Shaanxi Province, China</aff><aff>Shou-Bo Zhou, School of Biological Science, University of Manchester, Oxford Road, United Kingdom</aff></contrib-group><author-notes><fn><p>Author contributions: All authors contributed equally to the work.</p><p>Correspondence to: Chao Lou, Cell Engineering Research Centre, Fourth Military Medical University, Xi&#8217;an 710033,Shaanxi Province, China. <email>wall1970@sina.com</email></p><p>Telephone: +86-29-3374057</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>2</month><year>2002</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2002</year></pub-date><volume>8</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">261179</issue-id><fpage>69</fpage><lpage>73</lpage><history><date date-type="received"><day>19</day><month>7</month><year>2001</year></date><date date-type="rev-recd"><day>9</day><month>9</month><year>2001</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2001</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>02</month><year>2002</year></date></event><event event-type="pmc-live"><date><day>03</day><month>12</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-15 05:25:10.087"><day>15</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169;The Author(s) 2002. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2002</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="WJG-8-69.pdf"/><abstract><p>AIM: To label anti-hepatoma monoclonal antibody (mAb) fragment HAb18 F(ab&#8217;)<sub>2</sub> was labeled with <sup>188</sup>Re for the pharmacokinetic model of <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> and to evaluate its pharmacokinetic parameters in hepatoma-bearing nude mice.</p><p>METHODS: HAb18 F(ab&#8217;)<sub>2</sub> was directly labeled with <sup>188</sup>Re using 2-mercaptoethanol (2-ME) as reducing agents. Labeling efficiency and immunoreactivity of <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> were evaluated by Whatman 3MM paper chromatography and live cell assay, respectively. Biodistribution analysis was also conducted in nude mice bearing human hepatoma in which animals were sacrificed at different time points (1, 4, 18, 24 and 24 h) after <sup>188</sup>Re-HAb18 F (ab&#8217;)<sub>2</sub> was injected through tail-vein into hepatoma-bearing nude mice. The blood and radioactivity of organs and mass were measured. The concentrations of <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> were evaluated with apharmacokinetic 3P97 software.</p><p>RESULTS: The optimum labeling efficiency and immunoreactive fraction were 91.7% and 0.78% respectively. The parameters of <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> were: T<sub>1/2</sub>, 2.29 h; Vd,1.49 &#215; 10<sup>-9</sup> L&#183;Bq<sup>-1</sup>; AUC, 20. 49 &#215; 10<sup>9</sup> Bq&#183;h&#183;L<sup>-1</sup>;CL, 0.45 &#215; 10<sup>-3</sup> L&#183;h<sup>-1</sup>. <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> could locate specially in hepatoma with high selective reactivity of HAb18 F(ab&#8217;)<sub>2</sub>. <sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> was mainly eliminated by kidney. The maximal tumor to blood ratio was at 48 h, and maximal tumor to liver ratio was at 18 h.</p><p>CONCLUTION: The pharmacokinetics of <sup>188</sup>Re-HAb18 F (ab&#8217;)<sub>2</sub> fital-compartment model.<sup>188</sup>Re-HAb18 F(ab&#8217;)<sub>2</sub> can be uptaken selectively at the hepatoma site.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>